Objective To investigate the clinical effect of semaglutide combined with rosiglitazone in treatment of type 2 diabetes.Methods A total of 80 patients with type 2 diabetes admitted to the Department of Endocrinology of Huangshan Shoukang Hospital from May 2021 to July 2023 were selected and divided into control group and treatment group according to drug usage,with 40 patients in each group.Patients in control group were po administered with Rosiglitazone Maleate Tablets,4 mg/time,once daily.Patients in treatment group were sc administered with Semaglutide Injection on the basis of control group,0.25 mg/time,once weekly,and after 28 days,0.5 mg/time,once weekly.Both groups were treated continuously for 12 weeks.The clinical efficacy and symptom improvement time of two groups were observed.The changes of life quality,rating Scale(SF-36),glycated hemoglobin(HbA1c),fasting blood glucose(FPG),2 h blood glucose(2 h PG),fasting insulin(FINS),insulin resistance value(HOMA-IR)and islet beta cell value(HOMA-β)before and after treatment were compared between two groups.Results After treatment,the total effective rate of treatment group was 92.51%,which was significantly higher than that of control group(77.50%,P<0.05).After treatment,the improvement time of polyuria,polydipsia,polyfood,and body mass reduction in treatment group was significantly shorter than that in control group(P<0.05).After treatment,SF-36 scores in both groups were significantly higher than those before treatment(P<0.05).After treatment,the SF-36 score in the treatment group was higher than that in control group(P<0.05).After treatment,the levels of HbA1c,FPG,and 2 h PG in treatment group were significantly decreased compared with those before treatment(P<0.05).After treatment,the glucose metabolism index of treatment group was lower than that of control group(P<0.05).After treatment,FINS and HOMA-IR levels were significantly decreased,but HOMA-β levels were significantly increased in both groups(P<0.05).After treatment,FINS and HOMA-IR indexes in treatment group were lower than those in control group,but HOMA-β indexes were higher than those in control group(P<0.05).Conclusion The combination of semaglutide and rosiglitazone in treatment of type 2 diabetes can quickly improve the clinical symptoms of patients,and effectively regulate the related indexes of glucose metabolism,and significantly improve the quality of life of patients,which is worth learning and application.
NETL
NSTL
万方数据
